Evaluation of the clinical efficacy of accelerated photoactivated chromophore for keratitis-CXL for early to mid-stage fungal keratitis: a prospective, multicenter randomized controlled trial
International Ophthalmology · 18.07.2026 · 46 (1)
DOI: 10.1007/s10792-026-04173-w ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Ophthalmology, online erschienen am 18.07.2026. Verfasst von Xingli Zhou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Aier Eye Medical Center of Anhui Medical University, No.1899, Susong Road, Baohe District, Hefei, 230022, Anhui, People's Republic of China. Hauptthemen laut MEDLINE: Corneal Cross-Linking, Eye Infections, Fungal, Photosensitizing Agents, Riboflavin. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Capital health development research special fund.
Abstract (Originalsprache)
PURPOSE: To evaluate the clinical efficacy of accelerated photoactivated chromophore for keratitis-corneal collagen cross‑linking (PACK‑CXL) in early‑ to mid‑stage fungal keratitis. METHODS: This multicenter, prospective, randomized trial with masked outcome assessment enrolled patients with early‑ to mid‑stage fungal keratitis, randomizing them to either combined PACK‑CXL plus systemic and topical antifungals (CXL + M) or systemic and topical antifungals alone (M). Standardized examinations were performed at baseline and follow‑up visits. Five co‑primary endpoints (best‑corrected visual acuity, time to clinical healing, fungal density on confocal microscopy, time to clinical improvement, and corneal ulcer area) were assessed with Bonferroni correction (α = 0.01). RESULTS: A total of 49 patients were enrolled in this study. The CXL + M group showed superior efficacy on four co‑primary endpoints. Median time to clinical cure was halved (30 vs. 60 days; HR 2.76, 95% CI 1.40-5.44; P = 0.003), and median time to clinical improvement reduced from 14 to 7 days (HR 2.61, 95% CI 1.33-5.11; P = 0.005). Total disease burden (AUC for ulcer area and fungal density) was significantly lower (both P ≤ 0.003). BCVA change at 1 month did not differ between groups (P = 0.771). Corneal transplantation rate was lower in CXL + M (4.17% vs. 28.00%; P = 0.049). No adverse events occurred. CONCLUSIONS: This first RCT demonstrates that adjuvant accelerated PACK‑CXL significantly hastens clinical recovery, reduces disease burden and corneal transplantation rate, and shortens healing time in mild-to-moderate fungal keratitis, with a favorable safety profile. TRIAL REGISTRATION: The trial was registered on the Chinese Clinical Trial Registry ( www.chictr.org.cn , ChiCTR2000034467) and recorded with the National Medical Research Registration Information System, under the record number: MR-11-21-014401.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aier Eye Medical Center of Anhui Medical University, No.1899, Susong Road, Baohe District, Hefei, 230022, Anhui, People's Republic of China.
- Qinghai Aier Eye Hospital, No. 59, Xiguan Street, Xining City, Qinghai, People's Republic of China.
- Beijing Aier-Intech Eye Hospital, No. 12, Panjiayuan Nanli, Panjiayuan East Road, Chaoyang District, Beijing, People's Republic of China.
- Aier Eye Hospital, Jinan University, No. 2048, Huaqiang South Road, Futian District, Shenzhen, People's Republic of China.
- Liaoning Aier Eye Hospital, No. 11, Shi Yi Wei Road, Heping District, Shenyang, Liaoning, People's Republic of China.
- Hankou Aier Eye Hospital, No. 328, Machang Road, Jianghan District, Wuhan, Hubei, People's Republic of China.
Förderung
- Capital health development research special fund
Zitieren
APA
Zhou, X., Liu, C., Chen, T., Zeng, Q., Wu, S., Ren, Y., Lu, J., Bai, J., Li, L., Zhao, L., Hu, L., & Li, S. (2026). Evaluation of the clinical efficacy of accelerated photoactivated chromophore for keratitis-CXL for early to mid-stage fungal keratitis: a prospective, multicenter randomized controlled trial. International Ophthalmology, 46(1). https://doi.org/10.1007/s10792-026-04173-w
Vancouver
Zhou X, Liu C, Chen T, Zeng Q, Wu S, Ren Y, et al. Evaluation of the clinical efficacy of accelerated photoactivated chromophore for keratitis-CXL for early to mid-stage fungal keratitis: a prospective, multicenter randomized controlled trial. International Ophthalmology. 2026;46(1). doi:10.1007/s10792-026-04173-w
BibTeX
@article{Zhou2026,
author = {Zhou, Xingli and Liu, Chang and Chen, Tiehong and Zeng, Qingyan and Wu, Sangchao and Ren, Yi and Lu, Jing and Bai, Jie and Li, Ling and Zhao, Ling and Hu, Luping and Li, Shaowei},
title = {Evaluation of the clinical efficacy of accelerated photoactivated chromophore for keratitis-CXL for early to mid-stage fungal keratitis: a prospective, multicenter randomized controlled trial},
journal = {International Ophthalmology},
year = {2026},
volume = {46},
number = {1},
doi = {10.1007/s10792-026-04173-w}
}
EUVIMED